51
Views
0
CrossRef citations to date
0
Altmetric
Comment

Financial conflicts of interest between infectious diseases clinical practice guideline authors and the pharmaceutical industry in Japan

, , , , &
Pages 330-334 | Received 12 Jan 2024, Accepted 13 Jan 2024, Published online: 01 Feb 2024

References

  • Murayama A. Financial conflicts of interest among the authors of the clinical practice guidelines for rheumatoid arthritis in Japan. Cureus. 2023;15(10):e46650. doi: 10.7759/cureus.46650.
  • Murayama A, Kamamoto S, Murata N, et al. Evaluation of financial conflicts of interest and quality of evidence in Japanese gastroenterology clinical practice guidelines. J Gastroenterol Hepatol. 2023;38(4):565–573. doi: 10.1111/jgh.16089.
  • Hashimoto T, Murayama A, Mamada H, et al. Evaluation of financial conflicts of interest and drug statements in the coronavirus disease 2019 clinical practice guideline in Japan. Clin Microbiol Infect. 2022;28(3):460–462. doi: 10.1016/j.cmi.2021.11.019.
  • Murayama A, Saito H, Kamamoto S, et al. Evaluation of non-research payments from pharmaceutical companies to urologists in Japan between 2016 and 2019. Int Urogynecol J. 2023;34(6):1285–1292. doi: 10.1007/s00192-023-05463-y.
  • Murayama A, Kamamoto S, Saito H, et al. Pharmaceutical payments to Japanese board-certified dermatologists: a 4-year retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019. Sci Rep. 2023;13(1):7425. doi: 10.1038/s41598-023-34705-8.
  • Murayama A, Kamamoto S, Kawashima M, et al. Cross-sectional analysis of pharmaceutical payments to Japanese board-certified gastroenterologists between 2016 and 2019. BMJ Open. 2023;13(4):e068237. doi: 10.1136/bmjopen-2022-068237.
  • Medical Governance Research Institute, Tansa. Yen for Docs. Online database. Medical Governance Research Institute; [updated 2023 Dec 23]. Available from: https://yenfordocs.jp/.
  • Drazen JM. Revisiting the commercial-academic interface. N Engl J Med. 2015;372(19):1853–1854. doi: 10.1056/NEJMe1503623.
  • Rosenbaum L. Conflicts of interest: part 1: reconnecting the dots–reinterpreting industry-physician relations. N Engl J Med. 2015;372(19):1860–1864. doi: 10.1056/NEJMms1502493.
  • Murayama A, Yamada K, Yoshida M, et al. Evaluation of conflicts of interest among participants of the Japanese nephrology clinical practice guideline. Clin J Am Soc Nephrol. 2022;17(6):819–826. doi: 10.2215/CJN.14661121.
  • Murayama A, Ozaki A, Saito H, et al. Pharmaceutical company payments to dermatology clinical practice guideline authors in Japan. PLoS One. 2020;15(10):e0239610. doi: 10.1371/journal.pone.0239610.
  • Murayama A, Kamamoto S, Shigeta H, et al. Undisclosed financial conflicts of interest with pharmaceutical companies among the authors of the esophageal cancer practice guidelines 2017 by the Japan Esophageal Society. Dis Esophagus. 2022;35(10):doac056. doi: 10.1093/dote/doac056.
  • Schünemann HJ, Al-Ansary LA, Forland F, et al. Guidelines international network: principles for disclosure of interests and management of conflicts in guidelines. Ann Intern Med. 2015;163(7):548–553. doi: 10.7326/M14-1885.
  • Ngo-Metzger Q, Moyer V, Grossman D, et al. Conflicts of interest in clinical guidelines: update of U.S. Preventive services task force policies and procedures. Am J Prev Med. 2018;54(1S1):S70–S80. doi: 10.1016/j.amepre.2017.06.034.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.